ArriVent BioPharma, Inc. AVBP Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s total equity?
- ArriVent BioPharma, Inc. (AVBP) reported total equity of $323.98M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total equity changed year-over-year?
- ArriVent BioPharma, Inc.'s total equity increased by 60.0% year-over-year, from $202.54M to $323.98M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total equity?
- Over 3 years (2022 to 2025), ArriVent BioPharma, Inc.'s total equity has grown at a 53.4% compound annual growth rate (CAGR), from -$85.11M to $307.22M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.